Clinical Trials

Clinical Trials / Research

Newark Beth Israel Medical Center has a long standing history of participating in research for cancer and blood disorders. At present we conduct a wide variety of clinical trials in cancer and blood disorders.

For more information about our clinical trials, please call 973.926.7230

Open Protocols - Updated February 1, 2017

Breast Cancer

We are a member of NSABP and have open clinical trials.cancer research

NSABP B-51/RTOG 1304:
A Randomized Phase IIIClinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NSABP B-53/S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer

NSABP B-55/BIG 6-13
A Randomized, Double-Blind, Parallel Group, Placebo Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

NRG-BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

S1416
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

GI Cancer

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment, For Patients with Resected Head of Pancreas of Adenocarcinoma.

NSABP C-13:
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)

Blood Disorders

E1A11:Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone
(VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

ECOG E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in
Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Lung Cancer

S1403:A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124).

S1400:PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP)

Sub-Studies:

S1400I: “A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)” Initial Activation Effective 12/18/15.

Patient & Clinician Videos

For more information about clinical trials, watch these videos from the American Cancer Society:

Exploring the Options: Clinical Trials: in this video, learn more about cancer clinical trails options from the American Cancer Society.

Raising Awareness about Clinical Trials: A Video for Clinicians:in this video, learn more about how clinicians can help raise awareness for cancer clinical trails options from the American Cancer Society.

[ top ]